Valabrega G - Search Results

1

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, Mittica G, Giannone G, Robella M, Genta S, Lucchino F, Marocco F, Borella F, Valabrega G, Ponzone R. Ghisoni E, et al. Among authors: valabrega g. J Ovarian Res. 2018 May 30;11(1):42. doi: 10.1186/s13048-018-0415-y. J Ovarian Res. 2018. PMID: 29843747 Free PMC article.

2

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.

Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C, Colombo N. Lorusso D, et al. Among authors: valabrega g. Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023. Front Oncol. 2023. PMID: 37609387 Free PMC article.

3

ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

Valabrega G, Fagioli F, Corso S, Madon E, Brach del Prever A, Biasin E, Linari A, Aglietta M, Giordano S. Valabrega G, et al. Br J Cancer. 2003 Feb 10;88(3):396-400. doi: 10.1038/sj.bjc.6600735. Br J Cancer. 2003. PMID: 12569382 Free PMC article.

4

Trastuzumab-based combination therapy for breast cancer.

Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: valabrega g. Expert Opin Pharmacother. 2004 Jan;5(1):81-96. doi: 10.1517/14656566.5.1.81. Expert Opin Pharmacother. 2004. PMID: 14680438 Review.

5

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.

Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S. Valabrega G, et al. Oncogene. 2005 Apr 21;24(18):3002-10. doi: 10.1038/sj.onc.1208478. Oncogene. 2005. PMID: 15735715

6

Controversies in breast cancer: adjuvant and neoadjuvant therapy.

Montemurro F, Redana S, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: valabrega g. Expert Opin Pharmacother. 2005 Jun;6(7):1055-72. doi: 10.1517/14656566.6.7.1055. Expert Opin Pharmacother. 2005. PMID: 15957962 Review.

7

The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005.

Montemurro F, Valabrega G, Garetto L, Aliberti S, Grignani G, Ortega C, Leone F, Ponzone R, Aglietta M. Montemurro F, et al. Among authors: valabrega g. Expert Opin Pharmacother. 2005 Dec;6(16):2907-21. doi: 10.1517/14656566.6.16.2907. Expert Opin Pharmacother. 2005. PMID: 16318441

8

Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.

Montemurro F, Gatti M, Redana S, Jacomuzzi ME, Nanni D, Durando A, Popolo M, Ponzone R, Rossi A, Albieri V, Valabrega G, Sismondi P, Gabriele P, Aglietta M. Montemurro F, et al. Among authors: valabrega g. J Chemother. 2006 Feb;18(1):90-7. doi: 10.1179/joc.2006.18.1.90. J Chemother. 2006. PMID: 16572899

9

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.

Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M. Montemurro F, et al. Among authors: valabrega g. Oncologist. 2006 Apr;11(4):318-24. doi: 10.1634/theoncologist.11-4-318. Oncologist. 2006. PMID: 16614227 Free article.

10

Trastuzumab treatment in breast cancer.

Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: valabrega g. N Engl J Med. 2006 May 18;354(20):2186; author reply 2186. doi: 10.1056/NEJMc060852. N Engl J Med. 2006. PMID: 16707759 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters